Answers are grounded in this paper and cite their sources.
Tumor-mediated immune evasion is increasingly identified as a critical barrier limiting adoptive cell therapies in solid tumors. In our recently published paper in Cancer Research (2026; 86: 1956–67), we address this challenge by deploying a high-fidelity base-editing platform to permanently disrupt the TIGIT inhibitory checkpoint in primary natural killer (NK) cells. This intervention leads to the complete rebalancing of receptor-ligand interactions, suggesting that reprogramming endogenous receptor networks offers a more sophisticated alternative to conventional engineering.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: